Ligand (LGND) Breakout! Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout!

LGND 192.84

-1.7%

Jan 16 3:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Harrison Hickman who wrote (20369)	5/11/1998 9:08:00 AM
From: Henry Niman	Read Replies (1) of 32384

Here's a recent (May 6) BancAmerica Robertson Stephens Biotech report showing their BUY rec on LGND (it used to be a STRONG BUY): Several biotechnology companies are expected to have significant news events in the next few weeks. Below is a calendar of some of those events, the companies involved and the anticipated timing. We believe that the flow of news this month will help keep investment attention focused on the sector. Companies (Ticker - Rating) Dates Event MedImmune (MEDI - $53-1/8) 5/5 Analyst meeting (New York) Genzyme (GENZ - $31-7/16- NR) 5/6 Analyst meeting (Boston) Chiron/Cephalon (CHIR -$19- 11/16- LTA; CEPH- $13-15/16 - Buy) 5/12 User fee expiration for Myotrophin Ergo Science (ERGO -$17-5/16- NR) 5/14 FDA panel review of Ergoset for diabetes Genzyme (GENZ - NR) 5/15 FDA panel review of Thyrogen for thyroid cancer detection BioChem Pharma (BCHE $25-1/8- Buy) Amgen (AMGN - Buy) 5/16- 5/22 Digestive Disease Week (New Orleans) Sequus (SEQU- 12-1/16 - Strong Buy) Amgen (AMGN - Buy) Ligand (LGND -13-7/8- Buy) ImClone (IMCL-11-1/4 - MP) Immunex (IMNX- 72-1/4 - NR) Idec (IDPH -$35-3/8 NR) Coulter (CLTR - 28-3/4- NR) 5/16- 5/19 American Society of Clinical Oncology (Los Angeles) AMGN analyst briefing at ASCO (5/18) BioChem Pharma (BCHE - Buy) 5/22 Analyst meeting (Quebec) Centocor (CNTO-$41-1/8 - NR) 5/28 FDA panel review of Avakine for severe Crohn's disease Sequus (SEQU - Strong Buy) 5/29 Analyst meeting (New York)

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next